NYSE:RCUSBiotechs
Is Trial Failures And Gilead Pullback Altering The Investment Case For Arcus Biosciences (RCUS)?
On 20 April 2026, Arcus Biosciences and Gilead Sciences discontinued the Phase 3 STAR-121 and Phase 2 EDGE-Lung studies in metastatic non-small cell lung cancer after an Independent Data Monitoring Committee deemed the domvanalimab plus zimberelimab and chemotherapy arm futile, while zimberelimab plus chemotherapy showed overall survival in line with pembrolizumab plus chemotherapy.
Arcus also disclosed that Gilead will let certain option rights lapse in July 2026, narrowing access to...